Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of IBI362 Formulations in Healthy Chinese Males
NCT04773977Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Mar 2021
- Primary completion
- Mar 2021
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mazdutide in obesity (2 arms), sponsored by Innovent Biologics. Primary endpoint: Pharmacokinetic parameters at 8 weeks. Started Mar 2021; status: completed.
02
Drugs
mazdutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04773977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04773977.